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morphea, vitiligo, autoimmune hypothyroidism,
pneumonitis, autoimmune thrombocytopenic
purpura and central nervous system vasculitis.
Case report
Fabio Bonilla-Abadía1*, Evelyn Muñoz-Buitrón2,3, Carlos D Ochoa1, Edwin Carrascal4 and Carlos A Cañas1Abstract
Background: The localized scleroderma (LS) known as morphea, presents a variety of clinical manifestations that
can include systemic involvement. Current classification schemes divide morphea into categories based solely on
cutaneous morphology, without reference to systemic disease or autoimmune phenomena. This classification is
likely incomplete. Autoimmune phenomena such as vitiligo and Hashimoto thyroiditis associated with LS have
been reported in some cases suggesting an autoimmune basis. To our knowledge this is the first case of a
morphea forming part of a multiple autoimmune syndrome (MAS) and presenting simultaneously with
autoimmune thrombocytopenic purpura and central nervous system vasculitis.
Case presentation: We report an uncommon case of a white 53 year old female patient with LS as part of a
multiple autoimmune syndrome associated with pneumonitis, autoimmune thrombocytopenic purpura and central
nervous system vasculitis presenting a favorable response with thrombopoietin receptor agonists, pulses of
methylprednisolone and cyclophosphamide.
Conclusion: Is likely that LS have an autoimmune origin and in this case becomes part of MAS, which consist on
the presence of three or more well-defined autoimmune diseases in a single patient.
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The localized scleroderma (LS) is distinguished from
systemic sclerosis not only by the absence of vasospasm,
structural vascular damage, and involvement of internal
organs, but also by the distribution of the skin lesions.
LS, also known as morphea, presents a variety of clinical
manifestations that can include systemic nvolvement
[1]. Morphea is characterized by sclerosis of the skin
and in some cases underlying tissue. Current classifica-
tion schemes divide morphea into categories based
solely on cutaneous morphology, without reference to* Correspondence: fbac1982@hotmail.com
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distribution, and reproduction in any mediumsystemic disease or autoimmune phenomena. This clas-
sification is likely incomplete [2]. Autoimmune phe-
nomena such as vitiligo and Hashimoto thyroiditis
associated with LS have been reported in some cases
suggesting the possible autoimmune basis of morphea.
We report an uncommon case of LS as part of a mul-
tiple autoimmune syndrome associated with pneumon-
itis and central nervous system vasculitis.Case presentation
A 53 year old white female patient Jeovah witness was
referred to our institution because of general and re-
spiratory symptoms of several days consisting in malaise,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Vitiligo and morphea lesions on the lower limbs.
Figure 2 Histopathologic examination of the morphea lesions,
showing interstitial inflammation and the homogenization of
collagen (hematoxylin and eosin stain, magnification x100).
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cough, bleeding disorder compatible with idiopathic
thrombocytopenic purpura (ITP) and sudden headache
associated with diplopia and blurred vision. Her medical
history included localized scleroderma type morphea in
the lower limbs, vitiligo since 25 years ago, autoimmune
hypothyroidism, carpal tunnel and obesity.
At physical examination on admission, her cardiopul-
monary and abdominal examination was normal, no
evidence of oral ulcers, alopecia, malar rash, synovitis,
sclerodactyly, Raynaud phenomenon or dry symptoms.
Hypopigmented lesions of vitiligo were observed in the
lower limbs associated to atrophic violaceous plaques
(Figure 1), these last lesions showing interstitial inflam-
mation and homogenization of collagen in the histo-
pathology study which was consistent with morphea
(Figure 2). The neurological examination revealed diplopia
and mild dysmetria. Initial studies showed pulmonary infil-
trates and lung nodules of unclear etiology by X-ray and
chest tomography. A fiberoptic bronchoscopy was per-
formed evidenced only erythema of mucosa with negative
bacteriological cultures. Echocardiogram was reported as
normal. Laboratory test reported negative BK serial spu-
tum. Clotting studies, renal function, C-reactive protein,
bilirubin level and urine analysis were normal. Leukocytes
count of 9830 cells/mm3 with normal hemoglobin and dif-
ferential count and thrombocytopenia in the range ofFigure 3 MRI brain showed multiple cerebral infarctions with
hemorrhagic transformation.
Figure 4 Brain magnetic resonance angiography showed
irregularity in the pattern of cerebral arteries in "beads".
Bonilla-Abadía et al. BMC Research Notes 2012, 5:689 Page 3 of 5
http://www.biomedcentral.com/1756-0500/5/68941.000 which limited performing lung biopsy. Aspirate and
flow cytometry in bone marrow were reported as normal,
and there was no evidence of schistocytes in peripheral
blood spread. Abdominal ultrasonography not demon-
strated splenomegaly. Secondary infectious (HIV, hepatitis
B and C, blood and urine cultures) and drug-related causes
of thrombocytopenia were ruled. A brain computed
tomography (CT) reported right and left gangliobasal
and left lamellar intraventricular hemorrhage with ven-
tricular drainage without evidence of arteriovenous
malformation. Pulses of methylprednisolone were
initiated in the context of intracerebral bleeding and
autoimmune thrombocytopenia with unfavorable re-
sponse and due to the inability of transfusion, hyper-
immune human gamma globulin (0,5 gr/kg/day) was
indicated. Refractoriness was presented to the applica-
tion of gamma globulin and so it was necessary to use
thrombopoietin receptor agonists (Eltrombopag) with
a slow good response. Complementary autoimmune la-
boratory showed C3 136 mg/dl (90–180 mg/dl), C4
18 mg/dl (10–40 mg/dl), direct Coombs test, rheuma-
toid factor, Scl70, lupic anticoagulant, ANAs, Anti-
DNA, antineutrophil cytoplasmic antibodies (ANCAS)
and anticardiolipins titles within normal limits, as well as
extractable nuclear antigens (anti-Ro 7.7 U (<20), anti-
La 2.7 U (<20), anti-Sm 1.9 U (<20), and anti-RNP 4.8
U (<20)). The antimicrosomal (45 UI/ml) and anti-
thyroglobulin antibodies (21 UI/ml) were positive with
TSH in normal range. Control lung imaging showed
improvement of pulmonary involvement. Persistent head-
ache, photophobia, nausea, emesis and diplopia made it
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aangiography that reported multiple cerebral parenchymals
infarcts (right external capsule, left head caudate nucleus
and bilateral occipital) with hemorrhagic transformation
(Figure 3). Irregularity in cerebral arteries in "beads" pat-
tern compatible with central nervous system (CNS) vascu-
litis was observed (Figure 4). Intracranial neoplasms of a
primary and secondary nature, aneurysms and vascular
malformations were ruled out by this study. A diagnosis of
cerebral vasculitis was made in the light of findings requir-
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(1 gr monthly) with clinical improvement and satisfactory
recovery.
Discussion
LS associated with vitiligo and another autoinmune
phenommena like Hashimoto’s thyroiditis and auto-
immune thrombocytopenic purpura have been rarely
reported to occur simultaneously with evidence of im-
provement to treatment with systemic steroids [3-6].
Some studies have also indicated an association of auto-
immune diseases and an increased frequency of serum
autoantibodies with morphea [7]. In the literature, it has
been raised that this association is more than coincidence,
and it suggests an autoimmune basis for these conditions
[8]. In other studies, elevated serum cytokines and cell
adhesion molecules was related to the immune activation
of localized scleroderma [9], as well as decreased regula-
tory T cells in patients with morphea contributing to loss
of tolerance seen in this and other autoimmune diseases
[10,11]. Also some non–organ-specific autoimmune condi-
tions like systemic lupus erythematosus [12,13], rheumatoid
arthritis [14] and necrotizing vasculitis [15] have been
reported associated with LS, in the latter case requiring the
use of systemic steroids and cyclophosphamide with
gradual improvement. Central nervous system (CNS) in-
volvement and ophthalmologic manifestations in LS
has been reported by several authors and, particularly,
in linear scleroderma (en coup de sabre) and in pro-
gressive facial hemiatrophy [2,16] and a report of LS
associated with progressing ischemic stroke where it
is thought that was caused by hemodynamic distur-
bances from localized sclerotic obstruction of the
middle cerebral artery [17], however there are not
clearly reports of association between morphea and
central nervous system vasculitis. Table 1 summarizes
some of the reports of LS associated with autoimmune
diseases and the presence of autoantibodies. Is likely
that LS have an autoimmune origin and in this case
becomes part of a multiple autoimmune syndrome
(MAS), which consist on the presence of three or
more well-defined autoimmune diseases in a single
patient [18]. To our knowledge this is the first case of
a morphea forming part of a multiple autoimmune
syndrome and presenting simultaneously with ITP
and CNS vasculitis.
Conclusion
Is likely that LS have an autoimmune origin supported
by the reports described and its association with other
autoimmune diseases, in this case forming part of MAS
and with the aggravation to be associated with life-
threatening conditions requiring aggressive treatment.
This makes it important to look for systemic conditionsin patients with localized scleroderma that may worsen
the clinical localized disease.
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